Abstract: Methods and compositions are provided for improving tissue growth and device integration in vivo. Substrates and devices coated with an ?2?1 or ?5?1 integrin-specific ligand are provided. The substrates and devices coated with an ?2?1 or ?5?1 integrin-specific ligand are shown to have greater tissue formation on the surface relative to controls, in particular greater bone formation.
Type:
Grant
Filed:
September 19, 2007
Date of Patent:
February 14, 2012
Assignee:
Georgia Tech Research Corporation
Inventors:
Andres J. Garcia, Catherine D. Reyes, Timothy Petrie, Zvi Schwartz, Barbara D. Boyan, Jenny E. Raynor, David M. Collard, Abigail M. Wojtowicz, Robert E. Guldberg
Abstract: The present invention provides pharmaceutical compositions and methods for the instillation of lipid vehicles comprised of liposomes containing sphingomyelin or sphingomyelin metabolites to prevent, manage, ameliorate and/or treat disorders involving neuropathic pain and aberrant muscle contractions, such as what occurs in bladder hyperactivity disorders such as interstitial cystitis (IC) in animals or humans in need thereof. Also provided is a liposome-based delivery of drugs, e.g., antibiotics, pain treatments and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system and other organs or body systems. In particular, liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin and toxins, such as botulinum toxin is provided for the treatment of bladder conditions, including pain, inflammation, incontinence and voiding dysfunction.
Type:
Grant
Filed:
October 11, 2006
Date of Patent:
February 7, 2012
Assignee:
University of Pittsburgh
Inventors:
Michael B. Chancellor, Pradeep Tyagi, Matthew O. Fraser, Yao-Chi Chuang, William C de Groat, Leaf Huang, Naoki Yoshimura
Abstract: Disclosed herein are compositions and methods useful for promoting sperm motility, promoting embryonic stem cell formation, promoting trophoblast formation, or promoting neuronal growth. The compositions and methods are based on peptide sequences that bind trophinin, inhibit bystin-mediated arrest of epidermal growth factor (EGF) receptor, and promotes EGF receptor autophosphorylation.
Type:
Grant
Filed:
February 6, 2008
Date of Patent:
January 17, 2012
Assignee:
Sanford-Burnham Medical Research Institute
Abstract: A dressing for promoting healing and pain relief of the body of a living organism having a pathologic condition has at least one layer of conductive material having a resistance no greater than 1000 ?/cm2. When placed proximate a portion of the body of the living organism suffering from the pathologic condition, the dressing alters the electrodynamic processes occurring in conjunction with said pathologic condition to promote healing and pain relief in the living organism. When used as a wound dressing, the conductive material is placed in contact with tissue around the periphery of the wound and with the wound, lowering the electrical potential and resistance of the wound and increasing the wound current.
Abstract: Pellets containing an analgesic uniformly dispersed in a lipid carrier such as cholesterol mixed with fatty acid esters, can be used to provide long term pain relief. 5 mg cholesterol-tryglyceride-buprenorphine pellets released the majority of drug in 24-48 hours after implant and provide clinically significant plasma levels of analgesia in mice for 3-9 days. Blood levels of analgesia peak at day-1 and are substantially complete by day-5 depending on the level of buprenorphine. These results demonstrate that post surgical implants provide clinically significant levels of analgesia in the 24-48 hour period following surgery and thus obviate the time consuming, expensive, and high-risk need to inject mice post surgery. The pellets are safe and easy to use. Placed in the surgical wound at the end of surgery, they provide 2-3 days of analgesia and obviate the need for subsequent handling of the animal for pain therapy. The implants have no detectable effect on mouse behavior, hematology, or liver chemistry.
Abstract: Several novel PHA polymer compositions produced using biological systems include monomers such as 3-hydroxybutyrate, 3-hydroxypropionate, 2-hydroxybutyrate, 3-hydroxyvalerate, 4-hydroxybutyrate, 4-hydroxyvalerate and 5-hydroxyvalerate. These PHA compositions can readily be extended to incorporate additional monomers including, for example, 3-hydroxyhexanoate, 4-hydroxyhexanoate, 6-hydroxyhexanoate or other longer chain 3-hydroxyacids containing seven or more carbons. This can be accomplished by taking natural PHA producers and mutating through chemical or transposon mutagenesis to delete or inactivate genes encoding undesirable activities. Alternatively, the strains can be genetically engineered to express only those enzymes required for the production of the desired polymer composition. Methods for genetically engineering PHA producing microbes are widely known in the art (Huisman and Madison, 1998, Microbiology and Molecular Biology Reviews, 63: 21-53).
Abstract: An injectable formulation containing a rapid acting insulin and a long acting insulin has been developed. The pH of the rapid acting insulin is adjusted so that the long acting insulin, remains soluble when they are mixed together. Preferably, the formulation is administered before breakfast, provides adequate bolus insulin levels to cover the meal and basal insulin for up to 24 hours, and does not produce hypoglycemia after the meal. Lunch and dinner can be covered by two bolus injections of a fast, rapid, or very rapid acting insulin. Alternatively, by adjusting the ratio of rapid to long acting insulin, the long acting insulin may be shortened to a 12 hour formulation, and re-administered to the patient at dinner time, providing a safe and effective basal insulin level until morning. As a result, a patient using intensive insulin therapy should only inject three times a day.
Abstract: A compound of formula I: wherein X1, X2, X3, X4, Y1, Y2, Y3, Y4 and Z have meanings given in the description, and metallated forms of such compounds, which are useful in the treatment of medical conditions for which a photodynamic compound is indicated. Pharmaceutical formulations and methods of treatment of a medical condition for which a photodynamic agent is indicated are also disclosed. Sterilizing solutions comprising a compound of the invention, and the use thereof, are also disclosed.
Type:
Grant
Filed:
November 21, 2006
Date of Patent:
December 27, 2011
Assignee:
Destiny Pharma Limited
Inventors:
William Love, Derek Brundish, William Rhys-Williams, Xiang Dong Feng, Benoit Pugin
Abstract: Absorbable polyester fibers, braids, and surgical meshes with improved handling properties have been developed. These devices are preferably derived from biocompatible copolymers or homopolymers of 4-hydroxybutyrate. These devices provide a wider range of in vivo strength retention properties than are currently available and have a decreased tendency to curl, in the preferred embodiment, due to the inclusion of relaxation and annealing steps following extrusion and orientation of the fiber. Filaments prepared according to these methods are characterized by the following physical properties: (i) elongation to break from about 17% to about 85% (ii) Young's modulus of less than 350,000 psi, (iii) knot to straight ratio (knot strength/tensile strength) of 55-80% or (iv) load at break from 1100 to 4200 grams.
Abstract: Modified green tea polyphenols and methods of their use are provided. One aspect provides compounds and compositions containing green tea polyphenols with one on more ester-linked fatty acids.
Type:
Grant
Filed:
August 10, 2006
Date of Patent:
December 13, 2011
Assignee:
Georgia Health Science University Research Institute, Inc.
Abstract: Provided herein are compositions and methods of detecting Bcl-B expression in cancer cells to prognose, monitor, or select therapies for cancers such as breast cancer, prostate cancer, lung cancer, or gastric cancer.
Type:
Grant
Filed:
April 30, 2009
Date of Patent:
December 6, 2011
Assignee:
Sanford-Burnham Medical Research Institute
Abstract: Organisms are provided containing genes encoding one or more enzymes, Coenzyme-A-dependent aldehyde dehydrogenase, acyl-CoA transferase, acyl-CoA synthetase, ?-ketothiolase, acetoacetyl-CoA reductase and/or PHA synthase. In some cases one or more of these genes are native to the host organism and the remainder are heterologous genes provided by genetic engineering. These organisms produce poly (3-hydroxyalkanoate) homopolymers or co-polymers comprising 3-hydroxalkanoate monomers other than 3-hydroxybutryrate wherein these 3-hydroxyalkanoate units are derived from the enzyme-catalyzed conversion of alcohols to 3-hydroxyacyl-CoA monomers, where at least one step in the conversion pathway involves a Co-enzyme A-dependent aldehyde dehydrogenase activity. The PHA polymers are readily recovered and industrially useful as polymers for articles such as films, latexes, coatings, adhesives, fibers, binders, resins, and medical devices.
Abstract: The invention relates to a hybrid interfering RNA molecule comprising a duplex RNA and a single stranded DNA molecule and its use in the ablation of mRNA and in polymerase chain reactions.
Type:
Grant
Filed:
May 24, 2006
Date of Patent:
November 29, 2011
Assignee:
The University of York
Inventors:
Josephine Anne Milner, Michael Gait, Ming Jiang, Andrei Arzumanov
Abstract: Disclosed are isolated transposable elements, or isolated DNA sequences which encode a transposase protein or a portion of a transposase protein. The isolated transposable elements or the isolated DNA sequences are members of the mPing/Pong family of transposable elements. The invention also relates to a purified transposase protein, or peptide fragments thereof, encoded by such DNA sequences. Such transposable elements are useful in applications such as the stable introduction of a DNA sequence of interest into a eukaryotic cell. The sequence information disclosed herein is useful in the design of oligonucleotide primers which are useful for the isolation of related members of the mPing/Pong family of transposable elements, or for the detection of transpositions of the transposable elements.
Type:
Grant
Filed:
July 10, 2007
Date of Patent:
November 22, 2011
Assignees:
Washington University, University of Georgia Research Foundation, Inc.
Inventors:
Susan R. Wessler, Ning Jiang, Zhirong Bao, Xiaoyu Zhang, Sean R. Eddy
Abstract: Methods and compositions for delivering polynucleotides are provided. One embodiment provides a non-viral vector comprising a recombinant polynucleotide-binding protein comprising a protein transduction domain operably linked to a targeting signal. Methods for modifying the genome of non-nuclear organelles are also provided.
Abstract: Disclosed are compositions and methods for preventing or reducing harm resulting from pathogen infection. For example, disclosed are peptides that inhibit the processing of toxins normally cleaved by proprotein convertase enzymes.
Type:
Grant
Filed:
May 5, 2008
Date of Patent:
November 8, 2011
Assignees:
Socpra Sciences Sante Et Humaines, Illumina, Inc., Sanford-Burnham Medical Research Institute
Abstract: A novel costimulatory protein molecule, B7-DC, which is a member of the B7 family, is described as is DNA coding therefor and expression vectors comprising this DNA. B7-DC protein, fragments, fusion polypeptides/proteins and other functional derivatives, and transformed cells expressing B7-DC are useful in vaccine compositions and methods. Compositions and methods are disclosed for inducing potent T cell mediated responses that can be harnessed for anti-tumor and anti-viral immunity.
Type:
Grant
Filed:
October 31, 2007
Date of Patent:
November 8, 2011
Assignee:
The Johns Hopkins University
Inventors:
Drew M. Pardoll, Haruo Tsuchiya, Kevin S. Gorski, Su-Yi Tseng
Abstract: A novel costimulatory protein molecule, B7-DC, which is a member of the B7 family, is described as is DNA coding therefor and expression vectors comprising this DNA. B7-DC protein, fragments, fusion polypeptides/proteins and other functional derivatives, and transformed cells expressing B7-DC are useful in vaccine compositions and methods. Compositions and methods are disclosed for inducing potent T cell mediated responses that can be harnessed for anti-tumor and anti-viral immunity.
Type:
Grant
Filed:
October 31, 2007
Date of Patent:
November 8, 2011
Assignee:
The Johns Hopkins University
Inventors:
Drew M. Pardoll, Haruo Tsuchiya, Kevin S. Gorski, Su-Yi Tseng
Abstract: Methods are provided for determining the surface fatty acid content in a wood pulp or whitewater sample. The methods comprise reacting free fatty acids which are present on the surface of the wood pulp fibers in the sample or in the whitewater with one or more reagents to form a measurable species, and determining the fatty acid content from the quantitative measurement of the measurable species. The method is useful as a quick, portable, accurate and low cost assay for assessing the fatty acid content present at various sample points in pulp and paper mills. The method for determining the free fatty acid content can be conducted in a batch process (e.g., where samples are collected periodically and the test is conducted offline). Alternatively, the method for determining the free fatty acid content can be conducted in a continuous or semi-continuous process (e.g., online sampling/analysis).
Type:
Grant
Filed:
June 11, 2008
Date of Patent:
November 1, 2011
Assignee:
Enzymatic Deinking Technologies, LLC
Inventors:
Chengliang Jiang, Xiang H. Wang, Jianhua Ma, Robin M. Yezzi